BARDA selects Edesa's paridiprubart for U.S. government-funded Phase 2 ARDS trial

Edesa Biotech, Inc.

Paridiprubart (EB05) chosen by BARDA for a randomized, double-blind, placebo-controlled Phase 2 platform trial in all-cause ARDS.
Prior Phase 2 study showed paridiprubart reduced mortality by 84% among critically ill COVID-19 ARDS patients.
Edesa's ongoing Phase 3 study of paridiprubart in COVID-19 ARDS continues in Canada and the U.S.
BARDA contract managed via PPD (Thermo Fisher); Edesa supplies drug product and technical support.
Goal is to label paridiprubart as standard-of-care for all-cause ARDS, with biomarker sub-study to inform development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.